Aadi bioscience presents new nonclinical data demonstrating preferential tumor uptake of nab-sirolimus at the american society of clinical oncology (asco) annual meeting

Nab-sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mtor targets and greater antitumor activity compared to iv and oral mtor inhibitors in a xenograft model data support further clinical exploration of nab-sirolimus as a single agent or in combination los angeles , may 23, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced new nonclinical data demonstrating the significantly higher intratumoral drug concentration, stronger inhibition of mtor targets and greater antitumor activity of nab-sirolimus compared to intravenous and oral mtor inhibitors in a xenograft model. these data will be available as an abstract and published in the journal of clinical oncology supplement to coincide with the american society of clinical oncology (asco) annual meeting taking place may 31 – june 4, 2024.
AADI Ratings Summary
AADI Quant Ranking